The article presents the discussion on FDA approval of the first therapeutic monoclonal antibody (mAb). Topics include commercialization of recombinant insulin a few years earlier, marking the birth of a new class of medicines drastically reshaping the pharmaceutical landscape; and therapeutic or prophylactic potential with a layer of immense structural complexity highly demanding towards analytics.